TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8529777
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg d-alpha-tocopheryl acetate daily
Study: 8529777
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg d-alpha-tocopheryl acetate daily
Study: 15836974
Drug: Iyengar yoga
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iyengar yoga therapy
Study: 8172436
Drug: Low-dose radiation
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose radiation (2000 cGy to lymph node areas and 1000 to 1500 cGy to other involved organ sites)
Study: 16166579
Drug: tPA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: tPA treatment
Study: 27251051
Drug: Interferon beta-1a
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon beta-1a 30 mcg intramuscular once weekly
Study: 23614998
Drug: Preexposure prophylaxis
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preexposure prophylaxis (PrEP) with daily tenofovir disoproxil fumarate/emtricitabine
Study: 20092401
Drug: No vitamin
Normalized name: Vitamin B12 NOS
DrugBank: Cyanocobalamin (DB00115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No vitamin treatment (Group 1, n = 29)
Study: 26965503
Drug: 80-kV protocol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80-kV protocol B (PB; 1 g iodine/kg)
Study: 23981616
Drug: Intracoronary bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary bolus of tirofiban (10 µg/kg)
Study: 19079825
Drug: Critical comments
Normalized name: Critic-Aid Clear
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Critical comments (CC)
Study: 10383527
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg b.d. in H. pylori-negative patients
Study: 10383527
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg b.d. in H. pylori-positive patients
Study: 1683355
Drug: Intravenous ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous ribavirin therapy
Study: 6662177
Drug: Piretanide 6
Normalized name: piretanide 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piretanide 6 mg
Study: 25435886
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human growth hormone (rhGH)
Study: 2757878
Drug: Long acting
Normalized name: Long Acting Nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long acting propranolol 160 mg
Study: 2757878
Drug: Long acting
Normalized name: Long Acting Nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long acting propranolol 80 mg
Study: 19521532
Drug: Human PZQ
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human PZQ treatment only
Study: 7572539
Drug: Immunotherapy (IT)
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy (IT)
Study: 25163397
Drug: Everolimus plus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus plus zoledronic acid (4 mg intravenously 4-weekly)
Study: 25527749
Drug: Low-phenolic olive
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-phenolic olive oil (20 mL daily for 6 weeks)
Study: 28663651
Drug: Ondansetron 8
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 8 mg/4 ml
Study: 8596489
Drug: 75 g
Normalized name: Zosyn 3.375 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 g glucose in 225 mL water (33.3% solution)
Study: 31476924
Drug: Sulpiride 50
Normalized name: sulpiride 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulpiride 50 mg/d
Study: 20492060
Drug: Antihypertensive medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive medicine (control group)
Study: 16766594
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg L-AmB every other day (arm A)
Study: 12205253
Drug: Early introduction
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early introduction of oral feeding (initiated 48 hours after achieving full tube feeding, 120 kcal/kg/d)
Study: 12205253
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (oral feeding management left to discretion of attending physicians)
Study: 17958901
Drug: PG-116800 25
Normalized name: PG
DrugBank: 1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol)) (DB11331)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PG-116800 25 mg, taken twice daily for 12 months
Study: 11716450
Drug: Pentoxifylline 200
Normalized name: pentoxifylline 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline 200 mg/day for 3 days in 500 ml of saline over 3‐4 hours
Study: 27458234
Drug: Inhaled sodium
Normalized name: Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled sodium nitrite (90 mg)
Study: 24055176
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment satisfaction
Study: 17095972
Drug: Epidural analgesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural analgesia (EA) with continuous infusion of fentanyl and bupivacaine for 2 days after VATS
Study: 30311692
Drug: Percutaneous therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous therapy (PTNS) (30 min at 20 Hz and 200 cycles/s, once a week for 12 weeks)
Study: 16778461
Drug: Miconazole nitrate
Normalized name: Miconazole Nitrate
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Miconazole nitrate paste applied twice daily for 5 days at dosages of 1 and 2 mg/cm(2)
Study: 12208795
Drug: Long-term simvastatin
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term simvastatin treatment
Study: 27482615
Drug: Intravenous zoledronic
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous zoledronic acid (ZOL) 5 mg once yearly
Study: 12693324
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment only
Study: 25842457
Drug: Fluoride gel
Normalized name: Sodium Fluoride Gel
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride gel (FG) - 2% sodium fluoride
Study: 6286118
Drug: Chemotherapy control
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy control group (adriamycin, vincristine, VP16‐213 and cyclophosphamide) without PIVN.
Study: 28502503
Drug: Combined vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined vitamin D (50,000 IU every 2 weeks) + omega-3 fatty acids (1000 mg twice a day)
Study: 1728930
Drug: Serum cholesterol
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum cholesterol levels above 4.65 mmol/L (180 mg/dL)
Study: 16199428
Drug: Rosiglitazone 4
Normalized name: rosiglitazone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone 4 mg/day
Study: 24042367
Drug: Varenicline, 1
Normalized name: Varenicline, 1 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline, 1 mg twice daily for 12 weeks
Study: 9741602
Drug: Phonophoresis (PH)
Normalized name: PH-284
DrugBank: PH-284 (DB05452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phonophoresis (PH) with 0.05% fluocinonide gel
Study: 17895943
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion therapy
Study: 30987939
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone acetate (1000 mg once daily) plus prednisone (5 mg once daily) and ADT
Study: 22908694
Drug: Ferrous sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulfate (FeSO₄) 100 mg
Study: 22908694
Drug: Sodium iron
Normalized name: Sodium iron EDTA
DrugBank: Sodium feredetate (DB13381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium iron ethylenediaminetetraacetic acid (NaFeEDTA) 100 mg
Study: 8921053
Drug: Purified follicle
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified follicle stimulating hormone (FSH, Metrodin High Purity) administered either i.m. (MHPim) or s.c. (MHPsc)
Study: 2933998
Drug: Terbutaline 5
Normalized name: terbutaline 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline 5 mg t.i.d.
Study: 25186159
Drug: Pump therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pump therapy for 2 years
Study: 29151374
Drug: SAF oil
Normalized name: SAF-GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAF oil with 6 mg lutein (FloraGLO 20%)
Study: 12441211
Drug: lercanidipine 10
Normalized name: lercanidipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lercanidipine 10 mg/day
Study: 12441211
Drug: amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: amlodipine 5 mg/day
Study: 31818847
Drug: Benzodiazepine administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benzodiazepine administration
Study: 30300282
Drug: 24-hour urinary
Normalized name: Urinary hCG
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-hour urinary creatinine excretion and TIMP‐2/mOsm on day 1
Study: 23334069
Drug: Ponezumab 5
Normalized name: Ponezumab
DrugBank: Ponezumab (DB15135)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ponezumab 5 mg/kg
Study: 23334069
Drug: Ponezumab 10
Normalized name: Ponezumab
DrugBank: Ponezumab (DB15135)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ponezumab 10 mg/kg
Study: 21062338
Drug: Traditional platform
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional platform implants (control group)
Study: 19207079
Drug: Daptomycin monotherapy
Normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daptomycin monotherapy
Study: 16678643
Drug: Acetaminophen 4
Normalized name: acetaminophen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 4 g/d
Study: 12895183
Drug: Ciclopirox gel
Normalized name: Ciclopirox
DrugBank: Ciclopirox (DB01188)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciclopirox gel 0.77% applied twice daily for 28 days
Study: 1389821
Drug: Mixed infusions
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed infusions of propofol and alfentanil
Study: 31198144
Drug: Protocol 1
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol 1 (55 mL iodinated contrast media)
Study: 7856175
Drug: Pravastatin 10
Normalized name: pravastatin 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 10 mg/day
Study: 6981163
Drug: Low-dose trimethoprim
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose trimethoprim (TMP)
Study: 23439942
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of natural honey
Study: 12207597
Drug: Inpatient dithranol
Normalized name: Zithranol
DrugBank: Anthralin (DB11157)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient dithranol treatment
Study: 16546494
Drug: Oral medications
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral medications (oral laxative, digestant, defoaming agent)
Study: 24894651
Drug: EMD 1201081
Normalized name: Emdisterone
DrugBank: Drostanolone propionate (DB14655)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMD 1201081 0.32 mg/kg subcutaneously weekly plus cetuximab (combination)
Study: 19293071
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg
Study: 15915935
Drug: Fenspiride treatment
Normalized name: fenspiride
DrugBank: Fenspiride (DB08979)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenspiride treatment for 3 months
Study: 15915935
Drug: Fenspiride treatment
Normalized name: fenspiride
DrugBank: Fenspiride (DB08979)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenspiride treatment
Study: 12373041
Drug: anti-Ox-LDL titer
Normalized name: OX BILE
DrugBank: Ox bile extract (DB14016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-Ox-LDL titer on admission in patients who underwent thrombolytic therapy
Study: 24308693
Drug: Porcilis PRRS
Normalized name: Torilis japonica whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Porcilis PRRS vaccine
Study: 12662126
Drug: Rituximab 375
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab 375 mg/m(2) intravenously plus CHOP chemotherapy
Study: 30646422
Drug: Aspirin 75
Normalized name: aspirin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 75 mg
Study: 29482528
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (metformin + saxagliptin)
Study: 31352679
Drug: Prophylactic dose
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic dose of low-molecular-weight heparin
Study: 7847131
Drug: Intrathecal tissue
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal tissue plasminogen activator (rTPA) 10 mg in 10 ml solution, additional 5-10 mg for severe intraventricular bleeding
Study: 535832
Drug: Lithium carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lithium carbonate therapy
Study: 29075917
Drug: Observational treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observational treatment strategy
Study: 29075917
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment strategy
Study: 11192133
Drug: Clarithromycin extended-release
Normalized name: Clarithromycin Extended-Release Tablets
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin extended-release
Study: 2119446
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition (TPN) with standard amino acids (1.5 g/kg/day)
Study: 16782922
Drug: Black cohosh
Normalized name: black cohosh
DrugBank: Black cohosh (DB13975)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Black cohosh (Cimicifuga racemosa 20 mg BID)
Study: 22278333
Drug: Telcagepant 600
Normalized name: Telcagepant
DrugBank: Telcagepant (DB12228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telcagepant 600 mg
Study: 22278333
Drug: Telcagepant 900
Normalized name: Telcagepant
DrugBank: Telcagepant (DB12228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telcagepant 900 mg
Study: 17378909
Drug: Pantoprazole 8
Normalized name: pantoprazole 80 MG in 100 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 8 mg/h continuous IV infusion for 48 h
Study: 2700432
Drug: Cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 400 mg twice daily
Study: 15055092
Drug: High-strength magnetic
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-strength magnetic knee sleeve treatment
Study: 9156046
Drug: Insulin tolerance
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin tolerance test (0.15 U/kg body weight) in normal non-smokers
Study: 19840579
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg of clopidogrel (group I)
Study: 1098594
Drug: Quinestrol 4
Normalized name: quinestrol 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinestrol 4 mg
Study: 25989827
Drug: Reduced glutathione
Normalized name: Reduced glutathione
DrugBank: Glutathione (DB00143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced glutathione 1800 mg (n=416)
Study: 21059094
Drug: Linagliptin 10
Normalized name: empagliflozin-linagliptin 10 mg-5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linagliptin 10 mg
Study: 27434084
Drug: β-alanine supplementation
Normalized name: Alanine
DrugBank: Alanine (DB00160)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: β-alanine supplementation (1.2 g·d during 5 weeks of SIT)
Study: 30737835
Drug: Docetaxel with
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel with prednisone (5 mg twice daily for 3 cycles)
Study: 20651615
Drug: Docetaxel monotherapy
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel monotherapy
Study: 2981045
Drug: Human growth
Normalized name: Human growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human growth hormone (hGH) 7 IU subcutaneously daily for 2 months, followed by salmon calcitonin (CT), 100 MRC units every other day for 3 months, repeated twice after a 3 month rest period
Study: 2981045
Drug: Salmon calcitonin
Normalized name: Salmon calcitonin
DrugBank: Salmon calcitonin (DB00017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmon calcitonin (CT) given intermittently in the same time periods and at the same dose as in the coherence treatment group
Study: 28128852
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg GLE + 120 mg PIB with 800 mg once-daily RBV (arm B)
Study: 28128852
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg GLE + 120 mg PIB without RBV (arm C)
Study: 3392240
Drug: Acebutolol 400
Normalized name: acebutolol 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol 400 mg once daily
Study: 31366980
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg ascorbic acid
Study: 18386621
Drug: Embryonary peptides
Normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Embryonary peptides (EP) administered for 60 days
Study: 411398
Drug: Disodium cromoglycate
Normalized name: Disodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disodium cromoglycate (20 mg)
Study: 3034062
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (100 micrograms patch)
Study: 3034062
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (all doses)
Study: 12053828
Drug: Various treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatments for solar keratoses (specific interventions not detailed in the abstract)
Study: 16729787
Drug: Budesonide aqueous
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide aqueous nasal spray, 64 microg (32 microg per nostril) once daily for 1 year
Study: 11318767
Drug: Budesonide 400
Normalized name: Budesonide 400 microgram/actuation powder for inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 400 microg once daily in the morning
Study: 3503965
Drug: Serum physiologic
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum physiologic therapy
Study: 3503965
Drug: Amoxicillin +
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin + antihistaminic + nose drops therapy
Study: 16098233
Drug: Anti-HLA-DR antibody
Normalized name: Dr. Numb
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anti-HLA-DR antibody
Study: 17882235
Drug: Bright light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright light therapy for 4 weeks
Study: 29907198
Drug: Daily soap
Normalized name: Santalia Daily Cleanser Soap Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily soap and water bathing
Study: 31763984
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of allogeneic cardiosphere-derived cells (CDCs) - four escalating doses (37.5-75 million cells)
Study: 11678974
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (metformin + glimepiride)
Study: 23980620
Drug: Standard-dose stavudine
Normalized name: Stavudine
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-dose stavudine (30-40 mg)
Study: 23980620
Drug: Low-dose stavudine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose stavudine (20-30 mg)
Study: 16480404
Drug: Ranitidine 75
Normalized name: ranitidine 75 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 75 mg at bedtime
Study: 3816530
Drug: Positive incentive
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive incentive procedure (dose increase for drug-free urines)
Study: 3816530
Drug: Negative incentive
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative incentive procedure (dose decrease for drug-positive urines)
Study: 3816530
Drug: Dose decrease
Normalized name: Titanium Dioxide 7.2 g in 100 mL / Zinc Oxide 4 g in 100 mL TOPICAL LIQUID [Decree Daily Shield Broad Spectrum SPF 30 Sunscreen]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose decrease condition